NasdaqGM:MNKDBiotechs
Afrezza Pediatric Trial Grant Might Change The Case For Investing In MannKind (MNKD)
MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years.
This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care.
Next, we’ll examine how Breakthrough T1D’s grant backing for the INHALE-1...